RELEASE AND SETTLEMENT AGREEMENTRelease and Settlement Agreement • September 2nd, 2011 • Argos Therapeutics Inc • Pharmaceutical preparations • North Carolina
This Release and Settlement Agreement (“Agreement”) is entered into effective as of February 23, 2010 (the “Effective Date”) by and between Argos Therapeutics, Inc., a Delaware corporation (the “Company”), and Timothy W. Trost (“Employee”).
LICENSE AGREEMENTLicense Agreement • September 2nd, 2011 • Argos Therapeutics Inc • Pharmaceutical preparations • New York
This License Agreement, effective on the 28th day of July, 2011 (the “Effective Date”), is entered into by and between Celldex Therapeutics, Inc., a Delaware corporation having a principal place of business at 119 Fourth Avenue, Needham, MA 02494 (hereinafter “Celldex”) and Argos Therapeutics, Inc., a Delaware corporation having a principal place of business at 4233 Technology Drive, Durham, NC 27704 (“Argos”). Celldex and Argos are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
COLLABORATION TERMINATION AGREEMENTCollaboration Termination Agreement • September 2nd, 2011 • Argos Therapeutics Inc • Pharmaceutical preparations • New York
This Collaboration Termination Agreement (“Agreement”) dated the 31st day of December, 2009 (the “Termination Date”) is by and between Argos Therapeutics, Inc. (formerly known as Merix Bioscience, Inc.), a corporation organized and existing under the laws of the State of Delaware and having its principal office at 4233 Technology Drive, Durham, North Carolina 27704 (“Argos”), and Kyowa Hakko Kirin Co., Ltd. (formerly known as Kirin Brewery Company, Limited), a Japanese corporation having its principal office at 1-6-1 Ohtemachi, Chiyoda-ku, Tokyo, 100-8185 Japan (“KHK”).
